A new ViewRay MRIdian machine is the first of its kind in the UK and will be used by the University of Oxford, OUH and GenesisCare to help improve challenging cancer treatment through faster, tailored radiotherapy.
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.
Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for \u00a33.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.
A pathway designed to investigate individuals with non-specific but concerning symptoms of cancer wins the BMJ Awards 2020 Cancer Care Team of the Year.
Prof. Anne Kiltie and her team discuss their important work into the effects of radiosensitisation on ageing cancer patients with the CRUK Science Blog.
Congratulations to Professor Anna Schuh and her team who are the Winners of the Teamwork category in the Vice-Chancellor Innovation Awards 2020 for their work on SEREN_A Social Enterprise to deliver DNA-based diagnostics that improves outcomes of children and young adults with blood diseases in sub-Saharan Africa.
Understanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient\u2019s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.
UK Research and Innovation, Cancer Research UK and industry are investing more than \u00a311 million in an Oxford-led artificial intelligence (AI) research programme to improve the diagnosis of lung cancer and other thoracic diseases.
We are delighted to announce that three members of the Department of Oncology have been part of a project team which has been awarded a Vice-Chancellor's Education Award for 2020.
UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.
Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.
![\"None\"](\"https://www.oncology.ox.ac.uk/news/university-of-oxford-ouh-and-genesiscare-partnership-enables-access-to-state-of-the-art-radiotherapy-machine-in-oxford/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n